Erasca Announces Pricing of Upsized Public Offering of Common Stock

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced the pricing of an upsized public offering of 31.4 million shares at $17.50 per share, generating approximately $550 million in gross proceeds. The offering is expected to close on July 15, 2026, with proceeds to be used for R&D of product candidates and general corporate purposes.